DiSilvestro P et al, SOLO1 Investigators. Overall survival with maintenance olaparib at a 7-year follow-up in patients with newly diagnosed advanced OC and a BRCA mutation: The SOLO1/GOG 3004 trial. J Clin Oncol 2023;41(3):609-17. Abstract

Eskander RN et al. Overall survival and progression-free survival by PD-L1 status among endometrial cancer patients treated with pembrolizumab plus carboplatin/paclitaxel as compared to carboplatin/paclitaxel plus placebo in the NRG GY018 trial. SGO 2024;Late-breaking abstract.

Francoeur AA. Endometrial cancer and obesity trends in the United States in the 21st century. ASCO 2024;Abstract 5507.

González-Martín A et al. Progression-free survival and safety at 3.5 years of follow-up: Results from the randomised Phase III PRIMA/ENGOT-OV26/GOG-3012 trial of niraparib maintenance treatment in patients with newly diagnosed OC. Eur J Cancer 2023;189:112908. Abstract

Harter P et al. Durvalumab with paclitaxel/carboplatin (PC) and bevacizumab (bev), followed by maintenance durvalumab, bev, and olaparib in patients (pts) with newly diagnosed advanced ovarian cancer (AOC) without a tumor BRCA1/2 mutation (non-tBRCAm): Results from the randomized, placebo (pbo)-controlled phase III DUO-O trial. ASCO 2023;Abstract LBA5506.

Lheureux S et al. Phase II randomized multi-centre study of neoadjuvant olaparib in patients with platinum sensitive relapsed high grade serous ovarian cancer: The NEO trial. ASCO 2024;Abstract 5506.

Lorusso D et al. Pembrolizumab or placebo with chemoradiotherapy followed by pembrolizumab or placebo for newly diagnosed, high-risk, locally advanced cervical cancer (ENGOT-cx11/GOG-3047/KEYNOTE-A18): A randomised, double-blind, phase 3 clinical trial. Lancet 2024;403(10434):1341-50. Abstract

Makker V et al. Long-term follow-up of selinexor maintenance for patients with TP53wt advanced or recurrent endometrial cancer: A pre-specified subgroup analysis from the phase 3 ENGOT-EN5/GOG-3055/SIENDO study. ASCO 2024;Abstract 427956.

Makker V et al. Phase 3 dose selection for selinexor in TP53wt endometrial cancer based on exposure-response analysis. ASCO 2024;Abstract 5594.

Meric-Bernstam F et al. Efficacy and safety of trastuzumab deruxtecan in patients with HER2-expressing solid tumors: Primary results from the DESTINY-PanTumor02 phase II trial. J Clin Oncol 2024;42(1):47-58. Abstract

Moore KN et al. Mirvetuximab soravtansine in FRα-positive, platinum-resistant ovarian cancer. N Engl J Med 2023;389(23):2162-74. Abstract

Nishikawa T et al. Trastuzumab deruxtecan for human epidermal growth factor receptor 2-expressing advanced or recurrent uterine carcinosarcoma (NCCH1615): The STATICE trial. J Clin Oncol 2023;41(15):2789-99. Abstract

Oaknin A et al. Atezolizumab plus bevacizumab and chemotherapy for metastatic, persistent, or recurrent cervical cancer (BEATcc): A randomised, open-label, phase 3 trial. Lancet 2024;403(10421):31-43. Abstract

Pepin JT et al. Safety and tolerability of durvalumab + carboplatin/paclitaxel followed by durvalumab + olaparib in patients with newly diagnosed advanced or recurrent endometrial cancer (EC) in the DUO-E/GOG-3041/ENGOT-EN10 trial. ASCO 2024;Abstract 5599.

Pfisterer J et al. Optimal treatment duration of bevacizumab as front-line therapy for advanced OC: AGO-OVAR 17 BOOST/GINECO OV118/ENGOT Ov-15 open-label randomized Phase III Trial. J Clin Oncol 2023;41(4):893-902. Abstract

Pujade-Lauraine E et al. Maintenance olaparib rechallenge in patients with platinum-sensitive relapsed ovarian cancer previously treated with a PARP inhibitor (OReO/ENGOT-ov38): A phase IIIb trial. Ann Oncol 2023;34(12):1152-64. Abstract

Ray-Coquard I et al. Olaparib plus bevacizumab first-line maintenance in ovarian cancer: Final overall survival results from the PAOLA-1/ENGOT-ov25 trial. Ann Oncol 2023;34(8):681-92. Abstract

Rojas C et al. Vibostolimab coformulated with pembrolizumab (vibo/pembro) for previously treated advanced mismatch repair–deficient (dMMR) endometrial cancer: Results from cohort B1 of the phase 2 KEYVIBE-005 study. ASCO 2024;Abstract 5502.

Sánchez LM et al. Tisotumab vedotin in 2L/3L recurrent or metastatic cervical cancer: Subsequent therapy data from ENGOT-cx12/GOG-3057/innovaTV 301. ASCO 2024;Abstract 5531.

Simpkins F et al. Combination ATR and PARP Inhibitor (CAPRI): A phase 2 study of ceralasertib plus olaparib in patients with recurrent, platinum-sensitive epithelial ovarian cancer (cohort A). ASCO 2024;Abstract 5510.

Van Nieuwenhuysen E et al. Durvalumab + carboplatin/paclitaxel (CP) followed by durvalumab ± olaparib as first-line treatment for newly diagnosed advanced or recurrent endometrial cancer (EC) in DUO-E: Results by BRCA1/BRCA2 mutation (BRCAm) status. ASCO 2024;Abstract 5595.

Vergote I et al. innovaTV 301/ENGOT-cx12/GOG-3057: A global, randomized, open-label, phase III study of tisotumab vedotin vs investigator’s choice of chemotherapy in 2L or 3L recurrent or metastatic cervical cancer. ESMO 2023;Abstract LBA9.

Vergote I et al. Tisotumab vedotin in combination with carboplatin, pembrolizumab, or bevacizumab in recurrent or metastatic cervical cancer: Results from the innovaTV 205/GOG-3024/ENGOT-cx8 study. J Clin Oncol 2023;41(36):5536-49. Abstract

Westin SN et al. Durvalumab plus carboplatin/paclitaxel followed by maintenance durvalumab with or without olaparib as first-line treatment for advanced endometrial cancer: The phase III DUO-E trial. J Clin Oncol 2023;42(3):283-99. Abstract